Tags

Type your tag names separated by a space and hit enter

Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.
Expert Opin Pharmacother. 2015 Feb; 16(2):271-80.EO

Abstract

INTRODUCTION

Decisions regarding empirical antimicrobial therapy for complicated intra-abdominal infections (cIAIs) are increasingly difficult because of the threat of antimicrobial resistance. Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae are a particular challenge, as is multidrug-resistant (MDR) Pseudomonas aeruginosa, both of which are encountered in cIAI. Ceftolozane/tazobactam is a new antimicrobial that provides an effective solution for treating cIAI.

AREAS COVERED

Evidence concerning the mechanism of action of ceftolozane/tazobactam, its in vitro activity against common cIAI pathogens, and pharmacokinetic and pharmacodynamic properties are reviewed. The clinical efficacy and safety of ceftolozane/tazobactam plus metronidazole, as determined by the Phase II and III clinical trials in hospitalized adults with cIAI, are discussed.

EXPERT OPINION

Ceftolozane/tazobactam has demonstrated efficacy and safety in patients with cIAI, including those who are infected with ESBL-producing Enterobacteriaceae and P. aeruginosa. High rates of clinical cure by ceftolozane/tazobactam in Phase II and III trials suggest that this antimicrobial will be valuable for treating infections caused by MDR Gram-negative bacteria. In recent years, clinicians have become dependent on carbapenems for treating MDR infections. There is concern that this could lead to emergence of carbapenem-resistant strains, emphasizing the importance of antimicrobial stewardship. Ceftolozane/tazobactam appears to be an effective carbapenem-sparing alternative for treating cIAI.

Authors+Show Affiliations

Klinikum Peine, Academic Hospital of Medical University Hannover, Department of General, Visceral and Thoracic Surgery , Virchowstrasse 8h, D-31221, Peine , Germany +49 0 5171 931530 ; +49 0 5171 931549 ; christian.eckmann@klinikum-peine.de.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

25529765

Citation

Eckmann, Christian, and Joseph Solomkin. "Ceftolozane/tazobactam for the Treatment of Complicated Intra-abdominal Infections." Expert Opinion On Pharmacotherapy, vol. 16, no. 2, 2015, pp. 271-80.
Eckmann C, Solomkin J. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections. Expert Opin Pharmacother. 2015;16(2):271-80.
Eckmann, C., & Solomkin, J. (2015). Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections. Expert Opinion On Pharmacotherapy, 16(2), 271-80. https://doi.org/10.1517/14656566.2015.994504
Eckmann C, Solomkin J. Ceftolozane/tazobactam for the Treatment of Complicated Intra-abdominal Infections. Expert Opin Pharmacother. 2015;16(2):271-80. PubMed PMID: 25529765.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections. AU - Eckmann,Christian, AU - Solomkin,Joseph, Y1 - 2014/12/22/ PY - 2014/12/23/entrez PY - 2014/12/23/pubmed PY - 2015/5/12/medline KW - Gram-negative bacteria KW - ceftolozane/tazobactam KW - complicated intra-abdominal infection KW - enterobacteriaceae KW - multidrug resistance SP - 271 EP - 80 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 16 IS - 2 N2 - INTRODUCTION: Decisions regarding empirical antimicrobial therapy for complicated intra-abdominal infections (cIAIs) are increasingly difficult because of the threat of antimicrobial resistance. Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae are a particular challenge, as is multidrug-resistant (MDR) Pseudomonas aeruginosa, both of which are encountered in cIAI. Ceftolozane/tazobactam is a new antimicrobial that provides an effective solution for treating cIAI. AREAS COVERED: Evidence concerning the mechanism of action of ceftolozane/tazobactam, its in vitro activity against common cIAI pathogens, and pharmacokinetic and pharmacodynamic properties are reviewed. The clinical efficacy and safety of ceftolozane/tazobactam plus metronidazole, as determined by the Phase II and III clinical trials in hospitalized adults with cIAI, are discussed. EXPERT OPINION: Ceftolozane/tazobactam has demonstrated efficacy and safety in patients with cIAI, including those who are infected with ESBL-producing Enterobacteriaceae and P. aeruginosa. High rates of clinical cure by ceftolozane/tazobactam in Phase II and III trials suggest that this antimicrobial will be valuable for treating infections caused by MDR Gram-negative bacteria. In recent years, clinicians have become dependent on carbapenems for treating MDR infections. There is concern that this could lead to emergence of carbapenem-resistant strains, emphasizing the importance of antimicrobial stewardship. Ceftolozane/tazobactam appears to be an effective carbapenem-sparing alternative for treating cIAI. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/25529765/Ceftolozane/tazobactam_for_the_treatment_of_complicated_intra_abdominal_infections_ L2 - https://www.tandfonline.com/doi/full/10.1517/14656566.2015.994504 DB - PRIME DP - Unbound Medicine ER -